Zaccariotto Gabriel de Camargo, Bistaffa Maria Julia, Zapata Angelica Maria Mazuera, Rodero Camila, Coelho Fernanda, Quitiba João Victor Brandão, Lima Lorena, Sterman Raquel, Cardoso Valéria Maria de Oliveira, Zucolotto Valtencir
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics, University of São Paulo, São Paulo 13566-590, Brazil.
ACS Nano. 2025 May 6;19(17):16204-16223. doi: 10.1021/acsnano.4c15765. Epub 2025 Apr 9.
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.
癌症免疫疗法通过采用各种策略来教导免疫系统消除肿瘤,从而改变了肿瘤治疗的格局。其中,癌症纳米疫苗是一种新兴策略,它利用纳米技术增强针对肿瘤抗原的免疫激活。本综述阐述了该领域不同技术背后的原理,旨在产生强大而有效的免疫反应。讨论了用于设计纳米疫苗的策略多样性,包括活性剂类型、纳米载体、它们的功能化以及佐剂的掺入。此外,还探索了优化纳米颗粒制剂以增强抗原呈递、靶向免疫细胞和器官并促进强大而持久的抗肿瘤反应的策略。最后,我们分析了临床应用的现状,突出了正在进行的临床试验以及癌症纳米疫苗的未来潜力。本综述中提出的见解旨在指导该领域未来的研发工作,为开发更有效、更具针对性的纳米疫苗以对抗癌症做出贡献。
Acc Chem Res. 2020-10-20
J Control Release. 2022-11
Biomaterials. 2025-3
J Hematol Oncol. 2024-11-28
Nanomedicine (Lond). 2025-5
Theranostics. 2025-2-10
Nat Nanotechnol. 2024-11
J Control Release. 2024-9
Nat Rev Drug Discov. 2024-8
Research (Wash D C). 2024-6-18
Nat Commun. 2024-5-22
Comput Struct Biotechnol J. 2024-4-21